Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebo-controlled study.
about
Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections.Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase.The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers.Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus.Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavageCombating multidrug-resistant Gram-negative bacterial infections.Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.Frequency of Spontaneous Resistance to Peptide Deformylase Inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae.In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolatesSafety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor.
P2860
Q34596497-8CB2CAF5-9850-4536-B9E6-6D81A0AB0689Q35105814-C94A37D4-E7B9-452A-B39E-01EF3A0F734DQ35742017-84F0083C-3A4A-49A2-B8FF-734567DB2EDDQ37544388-40808A03-6582-4241-813D-4DE59954A328Q37544570-5EE35F20-85F8-4AE3-95E4-3237A0606C33Q38161570-7A6814A1-307B-4BD0-94D6-94BBE567D598Q40414549-74CF4067-9AE4-4779-B546-AB6DDFDD77A4Q41200948-2E79C5CE-A677-4C75-A3E7-E3B67FDB5372Q41687404-E64F58DE-1E4D-455E-B040-9FDABEECAFDEQ44621130-AA69F1A6-3042-4A7E-ADD3-D197C07BAAEF
P2860
Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebo-controlled study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Safety, tolerability and pharm ...... ized placebo-controlled study.
@en
type
label
Safety, tolerability and pharm ...... ized placebo-controlled study.
@en
prefLabel
Safety, tolerability and pharm ...... ized placebo-controlled study.
@en
P2093
P356
P1476
Safety, tolerability and pharm ...... ized placebo-controlled study.
@en
P2093
Etienne Dumont
Lori S Jones
Milena Kurtinecz
Odin J Naderer
P304
P356
10.1093/JAC/DKT097
P407
P577
2013-04-03T00:00:00Z